Skip to main content
. Author manuscript; available in PMC: 2014 Jun 20.
Published in final edited form as: Neuroscience. 2012 Dec 20;0:83–89. doi: 10.1016/j.neuroscience.2012.12.020

Figure 3. Effect of ICI 118,551 (β2 - selective adrenergic antagonist) on endothelin-1 (A) and epinephrine (B) induced mechanical hyperalgesia and stimulus-induced enhancement of their hyperalgesia.

Figure 3

Intradermal administration of ICI 118,551 (1 µg/paw) 15 min prior to endothelin, abolished stimulus-induced enhancement of endothelin hyperalgesia (A, P < 0.001, two way repeated measures ANOVA followed by Bonferroni post test, n = 8/group) without affecting the endothelin hyperalgesia. Intradermal administration of ICI 118,551 (1 µg/paw) 15 min prior to epinephrine abolished both epinephrine hyperalgesia and stimulus-induced enhancement of hyperalgesia (B, for both P < 0.001, two way repeated measures ANOVA followed by Bonferroni post test, comparing results within and between groups at different time points, n = 12/group).